|
| |
 |
| LETTER TO THE EDITOR |
|
| Year : 2016 | Volume
: 20
| Issue : 3 | Page : 413-414 |
|
HbA1c for diabetes screening in acute coronary syndrome: National Institute for Health and Care Excellence criteria and universal screening
Beuy Joob1, Viroj Wiwanitkit2
1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Tropical Medicine Unit, Hainan Medical University, Hainan, China
| Date of Web Publication | 11-Apr-2016 |
Correspondence Address:
Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.179989
How to cite this article:
Joob B, Wiwanitkit V. HbA1c for diabetes screening in acute coronary syndrome: National Institute for Health and Care Excellence criteria and universal screening. Indian J Endocr Metab 2016;20:413-4 |
How to cite this URL:
Joob B, Wiwanitkit V. HbA1c for diabetes screening in acute coronary syndrome: National Institute for Health and Care Excellence criteria and universal screening. Indian J Endocr Metab [serial online] 2016 [cited 2021 Mar 3];20:413-4. Available from: https://www.ijem.in/text.asp?2016/20/3/413/179989 |
Sir,
Diabetes mellitus (DM) is the global public health threat. The early detection for DM by screening is accepted as effective secondary prevention. For the patients with acute coronary syndrome (ACS), the screening is proved to be useful. The screening is recommended by National Institute for Health and Care Excellence (NICE) criteria.[1] NICE guidelines noted that all ACS patients with admission blood glucose concentrations above 11.0 mmol/l should have a fasting plasma glucose determination no earlier than day 4 after onset or have an HbA1c test before discharge.[2],[3]” The coverage and cost of the screening alternative are the big concern. McCune et al. mentioned that the universal coverage screening can be cost effective.[3] However, the concern on the coverage is still the issue to be investigated. Based on the previous report by McCune et al., using NICE criteria, 1 from 7 cases accepted for further screening whereas 26 from 49 cases accepted universal screening.[3] Based on this information, it can also confirm that the coverage of universal screening is better than the practice based on NICE criteria. Hence, it is confirmed that universal coverage screening for DM must be implemented for any ACS patients.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
 References | |  |
| 1. | Edge JA, Swift PG, Anderson W, Turner B; Youth and Family Advisory Committee of Diabetes UK. Diabetes services in the UK: Fourth national survey; are we meeting NSF standards and NICE guidelines? Arch Dis Child 2005;90:1005-9.  |
| 2. | NICE Clinical Guideline; CG130. Hyperglycaemia in Acute Coronary Syndromes: Management of Hyperglycaemia in Acute Coronary Syndromes. London: National Institute for Health and Care Excellence; 2013. Available from: http://www.guidance.nice.org.uk/CG130. [Last accessed on 2015 Dec 20] . |
| 3. | McCune C, Maynard S, McClements B, Lindsay JR. HbA1c for diabetes screening in acute coronary syndrome: Time for a reappraisal of the guidelines? Ulster Med J 2015;84:154-6. |
|
